The medical technology industry has not exactly had it easy in the last two years. In addition to the pandemic, which has shaken the industry, the MDR (Medical Device Regulation) of the EU and digitalisation in particular present companies with major challenges that tie up manpower and capital. In addition, there are now pandemic-related supply […]

Here we introduce you to the SHS senior advisors. The experience of these experts plays an important role for us in the investment process and benefits not least our portfolio companies. Professor Dr. rer. nat. Armin Bolz was Professor of Biomedical Engineering at KIT from 1999 to 2013. At the same time, he founded and […]

Founded in 2013, our portfolio company Lowenco is already one of the leading providers of ultra-low temperature solutions for the global biopharma industry after just a few years. A success that is also reflected in the company’s books. As of 31.12.2021, Lowenco reports an increase in operating profit of around 32 percent to now 80 […]

SHS is pleased to offer students a practical experience within the framework of an internship and to give them an insight into the areas of private equity, funds and growth companies. Since the beginning of July, we have been pleased to welcome Domenik Merdita (l.). Domenik is currently in the sixth semester of his business […]

Swiss TRI® Dental Implants is known for the state-of-the-art matrix® implant system without abutment for dental implants. matrix® is used in more than 50 countries worldwide. With the matrix® Digital Healing Abutment Library, TRI is now going one step further. This digital CAD library enables the rapid creation of patient-specific healing components and healing abutments […]

Tübingen / 18.08.2022 Manfred Ulmer-Weber has been appointed to the management board of SHS Gesellschaft für Beteiligungsmanagement mbH. Ulmer-Weber will be jointly responsible for the allocation of the new SHS VI fund of the Tübingen-based sector specialist. The additional Managing Partner is an SHS home-grown and started his career at SHS in 2010. The shareholders […]

SHS Gesellschaft für Beteiligungsmanagement has received capital commitments of over 220 million euros for its sixth fund at the first closing. Faster than expected, the Tübingen-based healthcare investor has already exceeded its target of 200 million euros at the first closing. The sixth SHS fund generation also aims at majority and minority investments in the […]

Pneumology deals with diseases of the respiratory tract and is a speciality of internal medicine. The word is derived from the Greek: pneumo = lung, logia = study. In medicine, the subject of pulmonary medicine has received special attention in the last two years through COVID-19. The history of pneumology begins much earlier, of course. […]

SHS is pleased to offer students a practical experience through an internship and to give you an insight into the areas of private equity, funds and growth companies. Simeon Liesenfeld has been an intern at SHS since the beginning of April 2022. Simeon is currently completing his bachelor’s degree in industrial engineering at the Karlsruhe […]

Kerstin Stuck is a new analyst in the SHS team. She is a biologist and business economist by training and thus doubly qualified to assess investment enquiries. In her spare time, she tends to her vegetable garden and chickens when she is not touring Europe in her caravan with her husband and children.

As a healthcare investor, SHS supports its portfolio companies not only with capital, but also with decades of experience and expertise in the healthcare sector. We wanted to know from Dr André Zimmermann, SHS partner and doctor of microbiology, what SHS specifically does for its portfolio companies. Editor: In which areas, apart from capital, does […]

The approval of the worldwide unique, double-walled high pressure balloon catheter “OPN-NC Super High Pressure PTCA Balloon” is a big step for SIS and very good news for all patients in the USA who are affected by serious lesions in the area of the heart vessels. More than 100,000 patients in Europe have already been […]